Skip to main content

Epigenetic Regulation of Immunotherapy Response in Triple-Negative Breast Cancer.

Publication ,  Journal Article
Llinàs-Arias, P; Íñiguez-Muñoz, S; McCann, K; Voorwerk, L; Orozco, JIJ; Ensenyat-Mendez, M; Sesé, B; DiNome, ML; Marzese, DM
Published in: Cancers (Basel)
August 17, 2021

Triple-negative breast cancer (TNBC) is defined by the absence of estrogen receptor and progesterone receptor and human epidermal growth factor receptor 2 (HER2) overexpression. This malignancy, representing 15-20% of breast cancers, is a clinical challenge due to the lack of targeted treatments, higher intrinsic aggressiveness, and worse outcomes than other breast cancer subtypes. Immune checkpoint inhibitors have shown promising efficacy for early-stage and advanced TNBC, but this seems limited to a subgroup of patients. Understanding the underlying mechanisms that determine immunotherapy efficiency is essential to identifying which TNBC patients will respond to immunotherapy-based treatments and help to develop new therapeutic strategies. Emerging evidence supports that epigenetic alterations, including aberrant chromatin architecture conformation and the modulation of gene regulatory elements, are critical mechanisms for immune escape. These alterations are particularly interesting since they can be reverted through the inhibition of epigenetic regulators. For that reason, several recent studies suggest that the combination of epigenetic drugs and immunotherapeutic agents can boost anticancer immune responses. In this review, we focused on the contribution of epigenetics to the crosstalk between immune and cancer cells, its relevance on immunotherapy response in TNBC, and the potential benefits of combined treatments.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Cancers (Basel)

DOI

ISSN

2072-6694

Publication Date

August 17, 2021

Volume

13

Issue

16

Location

Switzerland

Related Subject Headings

  • 3211 Oncology and carcinogenesis
  • 1112 Oncology and Carcinogenesis
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Llinàs-Arias, P., Íñiguez-Muñoz, S., McCann, K., Voorwerk, L., Orozco, J. I. J., Ensenyat-Mendez, M., … Marzese, D. M. (2021). Epigenetic Regulation of Immunotherapy Response in Triple-Negative Breast Cancer. Cancers (Basel), 13(16). https://doi.org/10.3390/cancers13164139
Llinàs-Arias, Pere, Sandra Íñiguez-Muñoz, Kelly McCann, Leonie Voorwerk, Javier I. J. Orozco, Miquel Ensenyat-Mendez, Borja Sesé, Maggie L. DiNome, and Diego M. Marzese. “Epigenetic Regulation of Immunotherapy Response in Triple-Negative Breast Cancer.Cancers (Basel) 13, no. 16 (August 17, 2021). https://doi.org/10.3390/cancers13164139.
Llinàs-Arias P, Íñiguez-Muñoz S, McCann K, Voorwerk L, Orozco JIJ, Ensenyat-Mendez M, et al. Epigenetic Regulation of Immunotherapy Response in Triple-Negative Breast Cancer. Cancers (Basel). 2021 Aug 17;13(16).
Llinàs-Arias, Pere, et al. “Epigenetic Regulation of Immunotherapy Response in Triple-Negative Breast Cancer.Cancers (Basel), vol. 13, no. 16, Aug. 2021. Pubmed, doi:10.3390/cancers13164139.
Llinàs-Arias P, Íñiguez-Muñoz S, McCann K, Voorwerk L, Orozco JIJ, Ensenyat-Mendez M, Sesé B, DiNome ML, Marzese DM. Epigenetic Regulation of Immunotherapy Response in Triple-Negative Breast Cancer. Cancers (Basel). 2021 Aug 17;13(16).

Published In

Cancers (Basel)

DOI

ISSN

2072-6694

Publication Date

August 17, 2021

Volume

13

Issue

16

Location

Switzerland

Related Subject Headings

  • 3211 Oncology and carcinogenesis
  • 1112 Oncology and Carcinogenesis